Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Blood Cancer Journal|July 26, 2012
Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemiaM Kaiser, A Kühnl, J Reins, et al.
Journal of Cancer Research and Clinical Oncology|January 7, 2014
Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)M Philipp, J Schwaab, C T Dietz, et al.
Leukemia|January 30, 2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failureM Agrawal, B Hanfstein, P Erben, et al.
Blood Cancer Journal|July 26, 2012
Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutationsM Neumann, S Heesch, N Gökbuget, et al.
Leukemia|June 9, 2006
Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networksF J T Staal, G Cario, G Cazzaniga, et al.
Journal of Critical Care|July 18, 2018
Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1-3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot studyT Boch, M Reinwald, B Spiess, et al.
Annals of Hematology|October 18, 2012
Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overloadF Nolte, B Höchsmann, A Giagounidis, et al.
Leukemia|June 17, 2005
Dlk1 in normal and abnormal hematopoiesisS Sakajiri, J O'kelly, D Yin, et al.
Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Pageof 7